MedTrace Logo

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

NCT04133337 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-10-21

No results posted yet for this study

Summary

The aim of this study was to investigate the safety and efficacy of SHR-1210 in combination with the anti-vascular survival target drug apatinib in patients with resectable NSCLC, and to provide new treatment options for neoadjuvant therapy in patients with the period IB-IIIA NSCLC.

Conditions

  • Lung Diseases
  • Neoplasms
  • Respiratory Tract Diseases
  • Thoracic Neoplasms
  • Non-small-cell Lung Cancer

Interventions

DRUG

Apatinib

Apatinib Mesylate Tablets

DRUG

SHR-1210

Camrelizumab for Injection

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    collaborator INDUSTRY

  • Sichuan Cancer Hospital and Research Institute

    lead OTHER

Principal Investigators

  • Juan Li, MD · Sichuan Cancer Hospital and Research Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2020-06-01
Completion
2021-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04133337 on ClinicalTrials.gov